These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 10859145

  • 1. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.
    Sweeny DJ, Lynch G, Bidgood AM, Lew W, Wang KY, Cundy KC.
    Drug Metab Dispos; 2000 Jul; 28(7):737-41. PubMed ID: 10859145
    [Abstract] [Full Text] [Related]

  • 2. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.
    Eisenberg EJ, Bidgood A, Cundy KC.
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1949-52. PubMed ID: 9303391
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.
    Koyama K, Takahashi M, Nakai N, Takakusa H, Murai T, Hoshi M, Yamamura N, Kobayashi N, Okazaki O.
    Xenobiotica; 2010 Mar; 40(3):207-16. PubMed ID: 20146556
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Oseltamivir.
    Bardsley-Elliot A, Noble S.
    Drugs; 1999 Nov; 58(5):851-60; discussion 861-2. PubMed ID: 10595865
    [Abstract] [Full Text] [Related]

  • 7. Biodistribution and metabolism of the anti-influenza drug [11C]oseltamivir and its active metabolite [11C]Ro 64-0802 in mice.
    Hatori A, Arai T, Yanamoto K, Yamasaki T, Kawamura K, Yui J, Konno F, Nakao R, Suzuki K, Zhang MR.
    Nucl Med Biol; 2009 Jan; 36(1):47-55. PubMed ID: 19181268
    [Abstract] [Full Text] [Related]

  • 8. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA.
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [Abstract] [Full Text] [Related]

  • 9. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.
    Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A.
    J Clin Pharmacol; 2000 Aug; 40(8):836-43. PubMed ID: 10934667
    [Abstract] [Full Text] [Related]

  • 10. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
    Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, Barrett J, Liu B, Ward P.
    Drug Metab Dispos; 2002 Jan; 30(1):13-9. PubMed ID: 11744606
    [Abstract] [Full Text] [Related]

  • 11. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
    Snell P, Oo C, Dorr A, Barrett J.
    Br J Clin Pharmacol; 2002 Oct; 54(4):372-7. PubMed ID: 12392584
    [Abstract] [Full Text] [Related]

  • 12. Metabolism of alpha-phosphonosulfonate squalene synthase inhibitors. I. Disposition of a farnesylethyl alpha-phosphonosulfonate and ester prodrugs in rats.
    Lan SJ, Hsieh DC, Hillyer JW, Fancher RM, Rinehart KJ, Warrack BM, White RE.
    Drug Metab Dispos; 1998 Oct; 26(10):993-1000. PubMed ID: 9763405
    [Abstract] [Full Text] [Related]

  • 13. Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment.
    Gillissen A, Höffken G.
    Med Microbiol Immunol; 2002 Dec; 191(3-4):165-8. PubMed ID: 12458353
    [Abstract] [Full Text] [Related]

  • 14. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
    Fukano Y, Kawazu K.
    Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
    Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P.
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):411-5. PubMed ID: 12910331
    [Abstract] [Full Text] [Related]

  • 16. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans.
    Dalvie D, Cosker T, Boyden T, Zhou S, Schroeder C, Potchoiba MJ.
    Drug Metab Dispos; 2008 Sep; 36(9):1869-83. PubMed ID: 18566038
    [Abstract] [Full Text] [Related]

  • 17. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.
    Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB.
    Antimicrob Agents Chemother; 1998 Mar; 42(3):647-53. PubMed ID: 9517946
    [Abstract] [Full Text] [Related]

  • 18. High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde.
    Eisenberg EJ, Cundy KC.
    J Chromatogr B Biomed Sci Appl; 1998 Sep 25; 716(1-2):267-73. PubMed ID: 9824240
    [Abstract] [Full Text] [Related]

  • 19. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O, Kessler N, Lina B.
    Antiviral Res; 2005 Oct 25; 68(1):43-8. PubMed ID: 16125799
    [Abstract] [Full Text] [Related]

  • 20. Distribution, metabolism and excretion of a synthetic androgen 7alpha-methyl-19-nortestosterone, a potential male-contraceptive.
    Prasad PV, Arumugam R, Willman M, Ge RS, Sitruk-Ware R, Kumar N.
    Steroids; 2009 Jan 25; 74(1):121-31. PubMed ID: 18992267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.